NNNN

Anbio Biotechnology Class A Ordinary Shares (NASDAQ:NNNN) is a German medical diagnostics company founded in 2021 and headquartered in Frankfurt am Main. The company specializes in developing and manufacturing <b>in vitro diagnostic (IVD) products</b>, particularly rapid testing solutions for infectious diseases. Anbio went public through an IPO in February 2025, capitalizing on the global demand for diagnostic testing that surged during the COVID-19 pandemic. The company has established an international presence, serving markets across Europe, Asia Pacific, North America, South America, and Africa through various distribution channels including over-the-counter retail, point-of-care testing facilities, and laboratory networks.